Dianthus Therapeutics (DNTH) PT Raised to $66 at Jefferies, 'We believe DNTH is undervalued'

Jefferies analyst Maury Raycroft raised the price target on Dianthus Therapeutics (NASDAQ: DNTH) to $66.00 (from $51.00) while maintaining a Buy rating.

The analyst comments "We believe DNTH is undervalued at ~$580M EV following (+)ve de-risking gMG ph.II data based on est $2B peak sales in gMG, CIDP, & MMN. Updates from maturing OLE can derisk pot'l monthly dosing. 2026 will be catalyst-rich: 1) ARGX's DM ph.II 1H26; 2) CIDP ph.III interim responder analysis 2H26; 3) MMN ph.II top-line 2H26; 4) 2H26 pivotal readouts from SNY (CIDP) & ARGX (MMN). PT to $66 (vs prior $51)."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'